Enliven Therapeutics, Inc. / Fundamentals

    Income statement

    Net revenue
    €0.00
    Cost of goods sold
    €138.14K
    Gross profit
    -€69.50K
    SG&A expenses
    €22.20M
    R&D expenses
    €75.82M
    EBITDA
    -€97.88M
    D&A
    €206.78K
    EBIT
    -€98.02M
    Interest expenses
    €0.00
    EBT
    -€86.38M
    Tax expenses
    -€429.00K
    Net income
    -€85.98M

    Cash flow statement

    Net deferred tax
    €0.00
    Non-cash items
    €1.55M
    Changes in working capital
    €4.17M
    Operating cash flow
    -€60.56M
    Capex
    €155.30K
    Other investing cash flow
    €730.16K
    Net investing cash flow
    -€187.18M
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €220.99M
    Debt repayment
    €0.00
    Other financing cash flow
    €78.79M
    Net financing cash flow
    €222.82M
    Foreign exchange effects
    €0.00
    Net change in cash
    €19.32M
    Cash at end of period
    €102.48M
    Free cash flow
    -€60.40M

    Balance sheet

    Cash and cash equivalents
    €102.48M
    Cash and short-term investments
    €420.85M
    Total receivables
    €0.00
    Inventory
    €0.00
    Other current assets
    €4.39M
    Total current assets
    €425.24M
    Property, plant & equipment
    €880.31K
    Goodwill
    €0.00
    Intangible assets
    €0.00
    Long-term investments
    €0.00
    Other non-current assets
    €6.21M
    Total non-current assets
    €7.09M
    Total assets
    €432.34M
    Accounts payable
    €2.02M
    Short-term debt
    €322.61K
    Other current liabilities
    €10.71M
    Total current liabilities
    €13.05M
    Long-term debt
    €0.00
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €175.03K
    Total non-current liabilities
    €175.03K
    Total liabilities
    €13.23M
    Common stock
    €50.62K
    Retained earnings
    -€255.13M
    Other equity
    -€151.87K
    Total equity
    €419.11M
    Total liabilities and shareholders' equity
    €432.34M

    Company information

    Market capitalization
    €1.01B
    Employees
    62
    Enterprise Value
    €860.30M

    Company ratios

    Gross margin
    0.0%
    EBITDA margin
    0.0%
    EBIT margin
    0.0%
    EBT margin
    0.0%
    Net margin
    0.0%
    ROE
    -20.5% Much worse than peer group: 145.2%
    ROA
    -19.9% Much better than peer group: -10,007.0%
    Asset turnover
    0.0%
    FCF margin
    0.0%
    FCF yield
    -6.0%
    Efficiency ratio
    0.0%
    Net sales per employee
    €0.00
    Net income per employee
    -€1.39M

    Notifications